Key result
Chronic treatment with tolvaptan significantly increased systolic right ventricular pressure and worsened right ventricular remodeling in a rat model of pulmonary arterial hypertension.
Why the study?
Does tolvaptan worsen pulmonary arterial hypertension and right ventricular remodeling in a SU5416/hypoxia/normoxia-exposed rat model?
Does tolvaptan worsen pulmonary arterial hypertension and right ventricular remodeling in a SU5416/hypoxia/normoxia-exposed rat model?
In a rat model of PAH, chronic vasopressin V2R antagonism with tolvaptan worsened pulmonary arterial pressure and right ventricular remodeling despite successful preload reduction.
Answers are grounded in this paper and cite their sources.
Raises caution for tolvaptan in pulmonary arterial hypertension; leaves open translation of V2 antagonism effects to human right ventricular remodeling.
BACKGROUND: The expression of vasopressin type 2 receptor (V2R) in the lung, and the long-term effects of tolvaptan, a selective V2R antagonist, on pulmonary circulation and right ventricular (RV) remodeling in a pulmonary arterial hypertension (PAH) rat model were evaluated. METHODS AND RESULTS: Six-week-old male Sprague-Dawley rats were injected subcutaneously with 20 mg/kg of SU5416 and were exposed to hypoxia for 3 weeks followed by re-exposure to normoxia for 7 weeks. These rats showed signs of RV failure and upregulation of V2R and cAMP in the lung tissue at 10 weeks after SU5416 injection. They were then treated with either 0.05% tolvaptan in diet (SUHx+Tolv) or normal diet (SUHx) during 5-10 weeks of SU5416 injection. Normal control rats (Cont) were also used for comparison. SUHx+Tolv had significantly higher pulmonary arterial pressure, more progressive pulmonary arterial remodeling, and more severe myocyte hypertrophy and interstitial myocardial fibrosis in the right ventricle compared with SUHx despite achieving successful preload reduction. CONCLUSIONS: Chronic vasopressin V2R antagonism may contribute to the worsening of PAH and the development of RV remodeling.
No takes yet. Share an insight, caveat, or question.
Goto et al. (2016) studied Pulmonary arterial hypertension and right heart failure (n=47). Tolvaptan vs. Normal diet (vehicle) was evaluated on Systolic right ventricular pressure (mmHg) (p=<0.05). Chronic treatment with tolvaptan significantly increased systolic right ventricular pressure and worsened right ventricular remodeling in a rat model of pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: